Navigation Links
At One Month Post-Launch, Nearly a Quarter of Surveyed U.S. Oncologists Have Prescribed Tafinlar for Malignant Melanoma, Compared to 15 Percent Who Used Mekinist
Date:10/22/2013

EXTON, Pa., Oct. 22, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that at one month post-launch, approximately one-quarter of surveyed U.S. medical oncologists have prescribed GlaxoSmithKline's BRAF-inhibitor Tafinlar for malignant melanoma, compared with 15 percent who report having prescribed GlaxoSmithKline's MEK inhibitor, Mekinist.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

According to the first wave of the LaunchTrends® Tafinlar/Mekinist report series, the inability to differentiate between Tafinlar and Mekinist from Roche/Genentech/Daiichi Sankyo's first-to-market BRAF-inhibitor Zelboraf is the greatest constrainer of medical oncologists' prescribing of these new market entrants. While use of Tafinlar and Mekinist in combination is not FDA-approved, surveyed oncologists believe combination therapy may represent the ultimate strategy for treating BRAF-mutated unresectable/metastatic malignant melanoma and provide the optimal platform for differentiation from Zelboraf.

The report also finds that approximately half of all surveyed U.S. medical oncologists are highly willing to prescribe Tafinlar and Mekinist as monotherapies, with more than three-quarters of nonprescribers reporting that they intend to prescribe Tafinlar and Mekinist within the next six months. For first-line BRAF-mutated unresectable/metastatic malignant melanoma, the highest percentage of surveyed U.S. medical oncologists indicated that they would prescribe Tafinlar in patients with brain metastases, whereas the highest percentage of surveyed U.S. medical oncologists reported they would be most likely to prescribe Mekinist in patients harboring the BRAF V600K mutation.

"Interestingly, almost 50 percent of surveyed U.S. medical oncologists indicated they would prescribe Tafinlar or Mekinist in BRAF-mutated unresectable/metastatic malignant melanoma in patients who had progressed on a first-line of Zelboraf," said Decision Resources Group Senior Business Insights Analyst Karen Pomeranz, M.Sc., Ph.D. "This use of Tafinlar and Mekinist arises despite only provisional evidence to suggest Tafinlar exhibits efficacy following treatment with Zelboraf. Moreover, Mekinist is specifically not indicated for treatment of patients who have progressed on prior BRAF-inhibitor therapy."

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com

 


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Hologic to Mark Start of Breast Cancer Awareness Month with NASDAQ Opening Bell Ceremony
2. At One Month Post-Launch, Nearly One-Quarter of Surveyed U.S. Medical Oncologists Have Prescribed Xofigo to Their Prostate Cancer Patients
3. Tecfideras Patient Share at Three Months Postlaunch Surpasses That for Aubagio and Gilenya At the Same Stage of Their Launches
4. Users of PediaVisions Spot Vision Screener Honor Childrens Eye Health and Safety Month with Back-to-School Screenings
5. International Isotopes Inc. Announces Second Quarter and Six Months 2013 Financial Results
6. One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs
7. For Multiple Sclerosis Treatment, Prescriber Base for Genzymes Aubagio Among U.S. Neurologists Has Increased Significantly at Six Months Post-launch, Compared to One and Three Months Post-launch
8. InspireMDs MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group
9. ALK Partners with AAFA to Launch New Online Resource for Allergic Patients During Allergy & Asthma Awareness Month
10. Pro-Dex, Inc. Announces Fiscal Third Quarter And Nine-Month Results
11. Addressing Hearing Loss Proves Win-Win for Both Employer and Employee, BHI Advises During National Employee Wellness Month
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... of the "Structural Electronics 2015-2025: Applications, Technologies, ... In-Mold Electronics, Smart Skin, ... Photovoltaics Structural electronics involves electronic ... load-bearing, protective structures, replacing dumb structures such as ...
(Date:6/24/2016)... Calif. , June 24, 2016  American Respiratory Labs (ARL), ... is now able to perform sophisticated lung assessments in patients, homes, ... , Inc. Patients are no longer limited to ... EasyOne PRO ® , ARL patients like Jeanne R. of ... in the comfort of her own home. ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
Breaking Medicine News(10 mins):